Digestive Diseases and Sciences

, Volume 60, Issue 8, pp 2446–2453 | Cite as

Effect of Immunosuppressive Therapies for the Treatment of Inflammatory Bowel Disease on Response to Routine Vaccinations: A Meta-Analysis

  • Douglas L. Nguyen
  • Emily T. Nguyen
  • Matthew L. Bechtold
Original Article



Several studies have evaluated the effect of immunosuppressive therapy for the treatment of inflammatory bowel disease (IBD) on response to routine vaccinations. The overall effect of specific classes of medications (i.e., immunomodulator vs. biologics) on vaccine response remains undefined. The aim of this study was to determine the effect of each class of immunosuppressive therapy in IBD patients on response to routine vaccinations.


A comprehensive search of PubMed/MEDLINE, Scopus, CINAHL, and Cochrane databases was performed (December 2014). All studies on adults comparing vaccine response among IBD patients on immunosuppression with non-immunosuppressed patients were included. Meta-analysis was performed using the Mantel–Haenszel (fixed effects) model with odds ratio (OR) to assess for adequate vaccine response.


In the pooled analysis of nine studies (N = 1474), we found that there was nearly a 60 % lower chance of achieving adequate seroprotection in the group that received immunosuppressive therapy compared to the group that was not on any immunosuppressive therapies (OR 0.41 95 % CI 0.30, 0.55, p < 0.001). Specifically, we also demonstrated that patients on immunomodulator monotherapy had a twofold higher probability of achieving adequate immune response to vaccination, compared to patients on anti-tumor necrosis factor (anti-TNF) monotherapy (OR 1.92 95 % CI 1.30, 2.84).


In conclusion, IBD patients on immunosuppressive therapy have a significantly lower response to routine vaccinations. The greatest effect is seen among patients on anti-TNF and combination immunosuppressive therapy. Routine monitoring of vaccine titers post-vaccination is important to ensure that adequate immunologic response has been achieved among IBD patients.


Immunosuppression Response to vaccination Anti-TNF therapy Inflammatory bowel disease 


  1. 1.
    Nguyen DL, Solaimani P, Nguyen ET, Jamal MM, Bechtold ML. Antitumor necrosis factor α is more effective than conventional medical therapy for the prevention of postoperative recurrence of Crohn’s disease: a meta-analysis. Eur J Gastroenterol Hepatol. 2014;26:1152–1159.PubMedCrossRefGoogle Scholar
  2. 2.
    Lu Y, Jacobson D, Bousvaros A. Immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:1417–1423.PubMedCrossRefGoogle Scholar
  3. 3.
    Yeung JH, Goodman KJ, Fedorak RN. Inadequate knowledge of immunization guidelines: a missed opportunity for preventing infection in immunocompromised IBD patients. Inflamm Bowel Dis. 2012;18:34–40.PubMedCrossRefGoogle Scholar
  4. 4.
    Melmed GY, Ippoliti AF, Papadakis KA, et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol. 2006;101:1834–1840.PubMedCrossRefGoogle Scholar
  5. 5.
    Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still’s disease. J Rheumatol. 2003;30:1624–1625.PubMedGoogle Scholar
  6. 6.
    López-Serrano P, Pérez-Calle JL, Sánchez-Tembleque MD. Hepatitis B and inflammatory bowel disease: role of antiviral prophylaxis. World J Gastroenterol. 2013;19:1342–1348.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997;46:1–24.Google Scholar
  8. 8.
    Askling J, Fored CM, Brandt L, et al. Time-dependent increase in risk of hospitalization with infection among Swedish RA patients treated with TNF antagonist. Ann Rheum Dis. 2007;66:1339–1344.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Fiorino G, Peyrin-Biroulet L, Naccarato P, et al. Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis. 2012;18:1042–1047.PubMedCrossRefGoogle Scholar
  10. 10.
    Coates T, Wilson R, Patrick G, et al. Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines. Clin Ther. 2001;23:392–403.PubMedCrossRefGoogle Scholar
  11. 11.
    Sands BE, Cuffari C, Katz J, et al. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:677–692.PubMedCrossRefGoogle Scholar
  12. 12.
    Melmed GY, Agarwal N, Frenck RW, et al. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105:148–154.PubMedCrossRefGoogle Scholar
  13. 13.
    Armijo-Olivo S, Stiles CR, Hagen NA, Biondo PD, Cummings GG. Assessment of study quality for systematic reviews: a comparison of the Cochrane Collaboration Risk of Bias Tool and the Effective Public Health Practice Project Quality Assessment Tool: methodological research. J Eval Clin Pract. 2012;18:12–18.PubMedCrossRefGoogle Scholar
  14. 14.
    Dotan I, Werner L, Vigodman S, et al. Normal response to vaccines in inflammatory bowel disease patients treated with thiopurines. Inflamm Bowel Dis. 2012;18:261–268.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Molnar T, Farkas K, Jankovics I, et al. Appropriate response to influenza A (H1N1) virus vaccination in patients with inflammatory bowel disease on maintenance immunomodulator and/or biological therapy. Am J Gastroenterol. 2011;106:370–372.PubMedCrossRefGoogle Scholar
  16. 16.
    Sempere L, Almenta I, Barrenengoa J, et al. Factors predicting response to hepatitis B vaccination in patients with inflammatory bowel disease. Vaccine. 2013;31:3065–3071.PubMedCrossRefGoogle Scholar
  17. 17.
    Altunoz ME, Senates E, Yesil A, et al. Patients with inflammatory bowel disease have a lower response rate to HBV vaccination compared to controls. Dig Dis Sci. 2012;57:1039–1044.PubMedCrossRefGoogle Scholar
  18. 18.
    Andrisani G, Frasca D, Romero M, et al. Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: effects of combined therapy with immunosuppressants. J Crohns Colitis. 2013;7:301–307.PubMedCrossRefGoogle Scholar
  19. 19.
    Cullen G, Bader C, Korzenik JR, et al. Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease. Gut. 2012;61:385–391.PubMedCrossRefGoogle Scholar
  20. 20.
    Gisbert JP, Villagrasa JR, Rodriguez-Nogueiras A, et al. Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. Am J Gastroenterol. 2012;107:1460–1466.PubMedCrossRefGoogle Scholar
  21. 21.
    Lee CK, Kim HS, Ye BD, et al. Patients with Crohn’’ disease on anti-tumor necrosis factor therapy are at significant risk of inadequate response to the 23-valent pneumococcal polysaccharide vaccine. J Crohns Colitis. 2014;8:384–391.PubMedCrossRefGoogle Scholar
  22. 22.
    Park SH, Yang SK, Park SK, et al. Efficacy of hepatitis A vaccination and factors impacting on seroconversion in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2014;20:69–74.PubMedCrossRefGoogle Scholar
  23. 23.
    Cossio-Gil Y, Martinez-Gomez X, Campins-Marti M et al. Immunogenicity of hepatitis B vaccine in patients with inflammatory bowel disease and the benefits of revaccination. J Gastroenterol Hepatol. 2014. (Epub ahead of print). doi:10.1111/jgh.12712.
  24. 24.
    Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929–936.PubMedCrossRefGoogle Scholar
  25. 25.
    Hutfless SM, Weng X, Liu L, et al. Mortality by medication use among patients with inflammatory bowel disease, 1996–2003. Gastroenterology. 2007;133:1779–1786.PubMedCrossRefGoogle Scholar
  26. 26.
    Recommended childhood immunization schedule–United States, 1997. Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 1997;46:35–40.Google Scholar
  27. 27.
    Shaye OA, Yadegari M, Abreu MT. Hepatotoxicity of 6-mercaptopurine (6-MP) and Azathioprine (AZA) in adult IBD patients. Am J Gastroenterol. 2007;102:2488–2494.PubMedCrossRefGoogle Scholar
  28. 28.
    Kobie JJ, Zheng B, Bryk P, et al. Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor. Arthritis Res Ther. 2011;13:R209.PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Wasan SK, Baker SE, Skolnik PR, Farraye FA. A practical guide to vaccinating the inflammatory bowel disease patient. Am J Gastroenterol. 2010;105:1231–1238.PubMedCrossRefGoogle Scholar
  30. 30.
    Gisbert JP, Menchen L. Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2012;35:1379–1385.PubMedCrossRefGoogle Scholar
  31. 31.
    Balint A, Farkas K, Eva PK, et al. Antibody and cell-mediated immune response to whole virion and split virion influenza vaccine in patients with inflammatory bowel disease on maintenance immunosuppressive and biological therapy. Scand J Gastroenterol. 2015;50:174–181.PubMedCrossRefGoogle Scholar
  32. 32.
    Gisbert JP, Villagrasa JR, Rodriguez-Nogueiras A, Chaparro M. Kinetics of anti-hepatitis B surface antigen titers after hepatitis B vaccination in patients with inflammatory bowel disease. Inflamm Bowel Dis.. 2013;19:554–558.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Douglas L. Nguyen
    • 1
  • Emily T. Nguyen
    • 2
  • Matthew L. Bechtold
    • 3
  1. 1.Department of Medicine, UC Irvine School of MedicineUniversity of California – IrvineOrangeUSA
  2. 2.Department of PharmacyUniversity of California – IrvineIrvineUSA
  3. 3.Department of MedicineUniversity of Missouri – ColumbiaColumbiaUSA

Personalised recommendations